A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

Part of paid clinical trials in Charlotte, North Carolina.

Sponsor
ARCE Therapeutics, Inc.
Study ID
NCT06906380
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia, in Relapsed or Refractory
  • MDS (Myelodysplastic Syndrome)

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Non interventional study — OTHER
    Non Intervention, an observation LTFU study

Study Details

This study will evaluate the long-term safety of ARD103 cellular therapies

Key Dates

Start date
Mar 15, 2026
Status verified
Dec 2025
Primary completion
May 30, 2040
Completion
Oct 31, 2040

Study Design

Enrollment
49 participants (estimated)

Arms

  • Arm: Non Interventional
    All subjects with AML or MDS who are enrolled in a parent study and were exposed to ARD103 CAR-T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study.

Primary Outcome Measure

The incidence and duration of AEs, SAEs, and AESIs related to ARD103 treatment. [ Time Frame: 15 years ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Novant Health Cancer InstituteCharlotteNorth Carolina28204
Kunal Shah
[email protected]
980-302-6297
Novant Health Cancer InstituteWinston-SalemNorth Carolina27201
Gait Jordan
[email protected]
336-718-8553
MD Anderson Cancer CenterHoustonTexas77030
Dr. Abhishek Maiti
[email protected]
713-745-3228

Find similar trials in Charlotte, NC

By research site
Novant Health Cancer Institute· Charlotte, NCNovant Health Cancer Institute· Winston-Salem, NCMD Anderson Cancer Center· Houston, TX

Related Studies